chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial unsolicited report received from a pharmacist on 08 April 2016. This case involves a female patient (age not reported) who was vaccinated with a dose of TDAP (dose, dose in series, batch number, route and site of administration were not reported) on an unspecified date (about year ago). Patient's medical history and concomitant medications were not reported. On an unspecified date, following the vaccination, the patient developed high fever. Patient's lab data and corrective treatment were not reported. On an unspecified date, patient had recovered. List of documents held by sender: none.
Mother reported "Hives" 24 hours after vaccine administration - "Hives" on neck - chest - back. Denies fever, resp. distress. Mother gave child oatmeal baths. Mom reports hives dissipated after 6 hours.
Acute chest pain , couldn't breathe, pain in the left arm , jaw neck , pressure in chest. Heart attack like symptoms
Doses administered past the published expiry; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment medication use was reported.
Facial paralysis, diagnosed with Bell's Palsy. Dx: Nov 27, 2007  8/22/08 Reviewed PCP medical records of 11/27-3/17/2008. FINAL DX: right-side Bell's palsy Records reveal patient experienced left facial swelling, HA & neck pain on 11/27/07.  Noted to have weak right facial muscles.  Tx w/steroids & off work x 1 week.  Improved but had residual right side muscle tenderness.  Developed flat red lesions, some scabbing, on back in 3/2008.  Dx w/shingles.
At 12 :40. when driving home after the flu shot, patient started to feel face tingle and feel tight. Heart was racing, she called her mom on her cell phone because she felt nervous. Went to her home and took Benadryl po 25 mg at 1 10 pm , and then drove to pick up son at daycare. At 545 pm and again at 11:05 pm took 25 mg po . Patient did call her primary physician, and they agreed with her treatment plan. Patient does not like to take medications, so she took the lower dose.
Individual given MOderna Covid Vaccine when should have been given Pfizer Covid Vaccine due to age (16 years old). No adverse affects were noted when family was notified.
c/o swelling, pain, redness @ inj site lt arm;swollen from shoulder to 1 inch away from elbow;seen by RN;advised warm compress placed on rt arm & if c/o discomfort from child;APAP given T98 ax;
DEVELOPED A FLUID FILLED RASH STARTING ON TRUNK AND MOVING TO THE REST OF HIS BODY FROM HEAD TO LEGS. BETWEEN 250-499 LESIONS. BEGAN TWO DAYS FOLLOWING VACCINATION. RASH WAS COMPLETELY SCABBED OVER BY 10/18/2016. NO REPORT OF FEVER OR OTHER SIGNS OF ILLNESS.
Patient received the COVID-19 Bivalent Booster vaccine on 1/5/2023. On 1/7/2023 patient was sent to the hospital due to hypotension and later expired.
rash in the injection site; it's slightly painful; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE RASH (rash in the injection site) and INJECTION SITE PAIN (it's slightly painful) in a 90-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history was provided.).    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Mar-2021, the patient experienced INJECTION SITE RASH (rash in the injection site) and INJECTION SITE PAIN (it's slightly painful). At the time of the report, INJECTION SITE RASH (rash in the injection site) and INJECTION SITE PAIN (it's slightly painful) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
VACCINE EXPOSURE DURING PREGNANCY; This prospective pregnancy case was reported by a healthcare professional and described the occurrence of vaccine exposure during pregnancy in a 24-year-old female subject who was vaccinated with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Boostrix, GlaxoSmithKline) for prophylaxis during pregnancy.   The subject's past medical history included one previous pregnancy resulting in normal birth of a full-term infant with no defects.  The subject had not been using contraception prior to becoming pregnant.  On an unspecified date the subject received a dose of Boostrix (intramuscular, unknown site), and experienced vaccine exposure during pregnancy.  Gestational age at the time of vaccination was unspecified.  Date of last menstrual period was 03 March 2011 and estimated date of delivery was 08 December 2011.  The conception was reported to be normal.  Prenatal testing including ultrasound on 26 July 2011 and maternal serum alpha-fetoprotein on 29 June 2011 had revealed no evidence of a defect.   Upon internal review done on 17th September 2019, the pregnancy outcome was updated to lost to follow-up.      Lab Comments: Lab Tests: Ultrasound on 26 July 2011 and maternal serum alpha-fetoprotein on 29 June 2011 revealed no evidence of a defect.
patient reports that he passed out before coming to ED, states felt nauseas. states received J&J vaccine yesterday, started having chills, nausea last night. denies V/D/fever.
Patient claims that she is hurting all over ever since this vaccination and believes the injection was given in her bone
This spontaneous report as received from a nurse refers to an unspecified number of patients of unknown demographics. No concurrent conditions or medical history were provided. On an unknown date, those patients were vacicnated with single doses of GARDASIL injection (strength, dose, route of administration, lot# and expiry date unspecified), post both supported and not supported temperature excursions. No concoitant medications were reported. No patient had reported experiencing an adverse effect due to receipt of vacination post temperature excursion. This is one of several reports from the same source. Additional information has been requested.
Night of vaccination went to sleep approximately 11pm with fatigue and nausea, awoke with lip angioedema. Unresolved with PO BENADRYL tx by Allergist with 0.50mL epinephrine, PO antihistamine (10mL ZYRTEC) 40 mg  Famotidine and 60 mg Prednisone with improvement of sxs.
reaction from inj sterile abscess;allergy to latex cap and plunger made of latex
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (injection site is swollen, very hard, and hot to the touch), VACCINATION SITE BRUISING (dark purple), MOBILITY DECREASED (can't move it), PARAESTHESIA (warm, tingling sensation) and VACCINATION SITE INDURATION (injection site is swollen, very hard, and hot to the touch) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. No Medical History information was reported. On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Apr-2021, the patient experienced VACCINATION SITE WARMTH (injection site is swollen, very hard, and hot to the touch), VACCINATION SITE BRUISING (dark purple), MOBILITY DECREASED (can't move it), PARAESTHESIA (warm, tingling sensation), VACCINATION SITE INDURATION (injection site is swollen, very hard, and hot to the touch) and VACCINATION SITE SWELLING (injection site is swollen, very hard, and hot to the touch). At the time of the report, VACCINATION SITE WARMTH (injection site is swollen, very hard, and hot to the touch), VACCINATION SITE BRUISING (dark purple), MOBILITY DECREASED (can't move it), PARAESTHESIA (warm, tingling sensation), VACCINATION SITE INDURATION (injection site is swollen, very hard, and hot to the touch) and VACCINATION SITE SWELLING (injection site is swollen, very hard, and hot to the touch) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No concomitant medications provided. No treatment information provided.
Pfizer was administered as 1st dose  Moderna was administered as the 2nd dose  Reported no symptoms except sore arm
Patient has CPX and flu in (L) thigh region. 14 days after vaccination started maculopap eryth. rash, started one spot patchy, now multiple, spreading red in an area of 2 x 2 inches. No syst. sympt.
Pt develop flat erythematous rash on chest and back.  Similar to folliculitis or nonviral pustulosis.  Good take.  Local itching at vaccination site.
After about 12 hours post vaccination, the person vaccinated felt itchiness first over both elbows arms and saw redness discoloration with feeling of warmth over the redness areas. She self-medicated  anti-allergic tabs of phenenephrine of 25 mg/tab as necessary  which subsided the itchiness.   However, the itching and redness kept coming on & off over the weekend which is very disturbing. Monday , she went to consult company clinic where 1 tablet of steroid [ Prednisone 10 mg] was orally taken that day and prescribed for 5 days.  The itching subsided and skin rashes mellow down a bit.  Yet still persisting on and off itching & redness present but milder since steroid was being taken.
pain on the left side only; rash; This case was reported by a consumer via interactive digital media and described the occurrence of pain localized in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced pain localized and rash. On an unknown date, the outcome of the pain localized and rash were unknown.   It was unknown if the reporter considered the pain localized and rash to be related to Shingles vaccine and Shingles vaccine.     Linked case(s) involving the same patient:  US2022AMR134386   Additional Information: GSK Receipt Date: 18-SEP-2022 Reporter's comment: This case was reported by a patient via interactive digital media. The patient had rash and pain on the left side only.  The patient wanted to know if it was common. Additional Supportive Information: The follow up would not possible, as no contact details were available.; Sender's Comments:  US-GSK-US2022AMR134386:Same reporter
Temp dysregulation (few days), headache(on and off), body aches(1day), fatigue(on and off), nausea(on and off), arm swelling/redness/tenderness(several days), stomach discomfort(few days). Rolaids, Tylenol, aleve, rest, water.
Acute erythematous rash- 7 days after MMR 1 diffuse, low grade fever, mild lymphadenopathy. ? attenuated Rubella.
Client went to emergency room approximately 24 hours after receiving first dose of HPV vaccine with complaints of difficulty breathing (wheezing).  Denied itching, rashes or history of asthma.  Denied sensation of throat closing. Pulse ox was 99%. Client was treated at the ER with Prednisone PO 60 mg; Pepcid PO 20 mg and Benadryl PO 50 mg with good results.  Discharged to home with instructions to follow up at Health Dept in 2-4 days.
Reports that "burn-like" lesion appeared 14days after vaccination on the LEFT shoulder about 1cm. Advised to follow up with PCP hx of Bechet's autoimmune disease.
caller had a stronger side effect reaction; she could feel where it went in; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient. Other Case identifier(s): US-PFIZER INC-2021620389 (Pfizer).  A 74 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2, for Covid-19 Immunization. The following information was reported: ADVERSE DRUG REACTION (non-serious), outcome "unknown", described as "caller had a stronger side effect reaction"; VACCINATION SITE IRRITATION (non-serious), outcome "unknown", described as "she could feel where it went in".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
fever; headache; This spontaneous case was reported by a patient and describes the occurrence of PYREXIA (fever) and HEADACHE (headache) in a 47-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No acute illnesses at the time of vaccination and up to one month before. No chronic or long-standing health conditions. Patient had no allergies to medications, food, and other products.  The patient's past medical history included COVID-19 (tested positive for COVID-19, through PCR, rapid test.) on 01-Jan-2022.   On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever) and HEADACHE (headache). At the time of the report, PYREXIA (fever) and HEADACHE (headache) outcome was unknown.            No concomitant medications were reported.  No treatment medications were reported.   This case was linked to MOD-2022-647149 (Patient Link).
Pt. vaccinated VARVAXI 3/17/14. Started with rash approx. 3/24/14 - seen 3/31/14 - rash verified by MD. Suspected post-vaccine chicken po.
One sided hearing loss; This case was reported by a pharmacist via call center representative and described the occurrence of hearing loss in a 59-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2015-2016 season) (batch number 33DR4, expiry date 30th June 2016) for prophylaxis.   On an unknown date, the patient received Fluarix Quadrivalent 2015-2016 season. On an unknown date, 7 days after receiving Fluarix Quadrivalent 2015-2016 season, the patient experienced hearing loss (serious criteria GSK medically significant). Fluarix Quadrivalent 2015-2016 season was continued with no change. On an unknown date, the outcome of the hearing loss was recovered/resolved.   It was unknown if the reporter considered the hearing loss to be related to Fluarix Quadrivalent 2015-2016 season.  Additional details were provided as follows: The age at vaccination was not reported. After receiving Fluarix Quadrivalent 2015-2016 season, the patient experienced one sided hearing loss beginning 7 days after vaccination and resolving 3 weeks later. The reporter did not consent to follow-up. This case was linked with case US2020145692, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020145692:same reporter
I attended an ?all vaccinated? event on Friday, 10/1. I had a mild headache beginning Monday, 10/4. On Wednesday, 10/6 I developed a severe headache, followed by nasal congestion, sneezing, swollen lymph node in throat, elevated temperature up to 99.5, and loss of smell and taste. I have been taking Advil, grapefruit seed extract, oregano oil, and xylitol nose spray to cope with symptoms. I stopped having a fever as of 10/11. I still cannot smell or taste as of 10/13.
Heart rate has going up and stabilizing; This spontaneous case was reported by a consumer and describes the occurrence of TACHYCARDIA (Heart rate has going up and stabilizing) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Heart disease, unspecified.    In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TACHYCARDIA (Heart rate has going up and stabilizing). At the time of the report, TACHYCARDIA (Heart rate has going up and stabilizing) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: high (High) heart rate has going up and stabilizing..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment medication was provided by reporter.  No concomitant medication was provided by reporter.
Cervical and clavicular lymphadenopathy on the left side; Some tenderness in neck; This is a spontaneous report from a contactable physician (patient). A 29-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number and Expiration Date were not reported), via an unspecified route of administration in left arm, on 17Dec2020 at 11:45, at a single dose, for COVID-19 immunization. The patient had no medical history and no concomitant medications. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The most recent COVID-19 vaccine was administered in the hospital. On 27Dec2020, the patient experienced cervical and clavicular lymphadenopathy on the left side (same side as the vaccine shot was received). The patient first noticed some tenderness in neck about 10 days after vaccine was administered. The events were considered non-serious. No treatment was received for the adverse events. Since the vaccination, the patient has not been tested for COVID-19. The patient had not recovered from the events.   Information about lot number and expiration date for the suspect product will be requested in follow-up attempts.
Hypertension, Tachycardia, Febrile (over 100.4) for 18 days, chills, severe systemic muscle & joint pain, burning pain, golf ball size lymph nodes, difficulty breathing, cough, asthma exacerbation, lungs sounds - wheezing, productive cough,  fatigue, flushing face (magenta colored), severe weakness, lethargy, mild peripheral edema, dizziness, decreased urine output, diarrhea, painful injection site, nausea, change in dreams.
On Sunday Sept 13, 2020 she started experiencing pain and sensitivity on her right side of face, eye and cheekbone. Diagnosis from provider and prescription for Valacyclovir 1 g tid on Sept 16, 2020
Patient states that after vaccine was administered, that evening a rash developed on her forearms. The rash continued to spread to her stomach and back over the course of the next two weeks. She sought medical treatment from a dermatologist who treated her with desoximetasome 0.05% ointment. After no resolution she visited another provider who has treated her with Cephalexin 500 mg and Ketoconazole 200 mg. The rash has not resolved.
two softball sized red lumps located on each arm injection site that were hot; This is a spontaneous report from contactable pharmacist via Pfizer Sales Representative.   A 67-year-old (probably between the age of 66 and 68) female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) via an unspecified route of administration at single dose on an unspecified date in 2019 for immunisation, at physician's office.  The patient medical history and concomitant medications were not reported.  On an unspecified date in 2019 after the shot, while in the pharmacy, she showed pharmacy manager two softball sized red lumps located on each arm injection site that were hot to the touch and were results of the vaccinations. She showed pharmacy manager this about a week before this report. The outcome of the event was unknown.
poss tonic-clonic activity of upper & lower extremities, intermittently over 6-12 hrs w/in 24 hrs of DTP vax;
Per patient when she got home later that day it was very large and raised 5cm. X 5cm.  That night she could not move it and it had fever.  The next day the fever and pain had gone and a large goose egg remained.
Information has been received from a registered nurse indicated that their practice has recently see 4 cases of cellulitis with VARIVAX (Merck). It's unknown if the patients had sought any medical attention. Attempts are being made to obtain additional identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided if available. This is one of several reports from the same source. Additional information has been requested.
My grandson started feeling sick, lost sensation in limbs and was in extrem pain. Was diagnosed with Guillain-Barre syndrome. He was given IV imun-globulin treatment. Later, doctors said he did not have Guillain-Barre syndrome. Syndrome.  The doctors said they didn't know what the illness was. After 30 days in the Hospital, 30 days after the onset of sickness, my Grandson looked like a polio victim. He was paralyzed and could not use his legs, which had atrophied into little spindles, he couldn't lift his  arms higher than his shoulders, he had last 30 lbs. and had no left  appetite. He was depressed and with-drawn. The doctors said they had no diagnosis for what he was suffering. The initial pain was so intense he was given phentenal patches. The doctors wanted my Grandson to stay in the hospital another 30 days. It seemed, at that point, that my Grandson was dying. The family decided to take   him out of the hospital and bring him home. The doctors then decided on a diagnosis: psychosomatic. At home, my grandson began to make progress in healing, little by little. He can walk now, but can not run and play sports like he used. He no longer likes to read and has difficulty  concentrating. His food allergies have sky-rocketed. My grandson and our family have experienced pure evil in the form of Gardasil, the HPV vaccine. Gardasil is a crime against  humanity. How long will this travesty go on for?
Client was monitored after being Vaccinated for 15 minutes and staff observed no symptoms. DHS CRT was made aware of the death two days prior to 2nd dose Vaccine Clinic.
This case was reported by a consumer and described the occurrence of pain in arm in a adult male patient who received SHINGRIX for prophylaxis. On 30th September 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm was unknown.  It was unknown if the reporter considered the pain in arm to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient returned to the same pharmacy where the vaccination was performed one week later, on 5th October 2018, and got the flu shot. The patient told the pharmacist that they just had their SHINGRIX shot the week before in their left arm so better give me the flu shot in their right arm. Today The patient was told by the pharmacist who gave them the SHINGRIX shot that the patient was supposed to wait at least 2 weeks after the SHINGRIX shot to get a flu shot. The patient asked whether the effectiveness of either of the vaccine be lessened because the patient got them so close together. The patient had not had side effects from either shot except a slightly sore upper arm from the SHINGRIX.